Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Tumor-targeted in vivo gene silencing via systemic delivery of cRGD-conjugated siRNA

15 Sept 2014

Abstract excerpt

RNAi technology is taking strong position among the key therapeutic modalities, with dozens of siRNA-based programs entering and successfully progressing through clinical stages of drug development. To further explore potentials of RNAi technology as therapeutics, we engineered and tested VEGFR2 siRNA molecules specifically targeted to tumors through covalently conjugated cyclo(Arg-Gly-Asp-d-Phe-Lys[PEG-MAL])...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Advanced biosensing and bioanalysis techniques
Share to Cell Adhesion Molecules Research
Share to RNA Interference and Gene Delivery

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 25223783
DOI: 10.1093/nar/gku831

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Tumor-targeted in vivo gene silencing via systemic delivery of cRGD-conjugated siRNAPMID 25223783Read ↗

Non-cationic RGD-containing protein carrier for tumor-targeted siRNA deliverySemantic proximity Read ↗

CRISPR-Cas9 genome editing using targeted lipid nanoparticles for cancer therapySemantic proximity Read ↗

Cellular Uptake and Fate of Cationic Polymer-Coated Nanodiamonds Delivering siRNA: A Mechanistic StudySemantic proximity Read ↗

Tumor regression by targeted gene delivery to the neovasculature.Semantic proximity Read ↗

Nano-based delivery of RNAi in cancer therapySemantic proximity Read ↗

Systematic Targeting of GD2‐Positive Neuroblastoma Tumors With a Photooncolytic Phage Nanovector PlatformSemantic proximity Read ↗

Cancer siRNA therapy by tumor selective delivery with ligand-targeted sterically stabilized nanoparticle.Semantic proximity Read ↗

Antibody targeting facilitates effective intratumoral siRNA nanoparticle delivery to HER2-overexpressing cancer cellsSemantic proximity Read ↗

Cancer Therapy with Nanoparticle-Medicated Intracellular Expression of Peptide CRM1-Inhibitor.Semantic proximity Read ↗

Suppression of ocular neovascularization with siRNA targeting VEGF receptor 1Semantic proximity Read ↗

<i>In Vivo</i> Targeting of Tumor Endothelial Cells by Systemic Delivery of Lentiviral VectorsSemantic proximity Read ↗

In vivo optical imaging of integrin αV-β3 in mice using multivalent or monovalent cRGD targeting vectorsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.